Is reduced systemic heparinization justified with heparin-bonded bypass circuits in cardiac surgery? - Experience with and without aprotinin

Transfusion and Apheresis Science

Volumn 29, Issue 1, 2003, Pages 17-24

  Kipfer, Beat ^a   Englberger, Lars ^a   Gygax, Erich ^a   Nydegger, Urs ^a   Carrel, Thierry ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Aprotinin; Blood coagulation; Cardiopulmonary bypass (CABG); Heparin; Inflammation

Indexed keywords

ANTIFIBRINOLYTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIPLASMIN; APROTININ; D DIMER; FIBRINOPEPTIDE A; HEPARIN; INTERLEUKIN 6; LACTOFERRIN; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTAMINE SULFATE; SOLUBLE TUMOR NECROSIS FACTOR ALPHA RECEPTOR 2; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; BLOOD CLOTTING TIME; BYPASS SURGERY; CELL ACTIVATION; CLINICAL ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DATA ANALYSIS; DRAIN; DRUG EFFECT; ELECTIVE SURGERY; EQUIPMENT; EXPERIENCE; FEMALE; HEART SURGERY; HEMOSTASIS; HEPARINIZATION; HUMAN; INFLAMMATION; LEUKOCYTE; LEUKOCYTE ACTIVATION; LOW DRUG DOSE; MALE; MEASUREMENT; MEDIASTINUM; MORBIDITY; PERIOPERATIVE PERIOD; PUMP; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SURFACE PROPERTY; SURGICAL MORTALITY; SYSTEMIC CIRCULATION; THROMBUS;

EID: 0038160779     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-0502(03)00095-8     Document Type: Conference Paper

References (22)

1. Steinberg B.M., Grossi E.A., Schwartz D.S.et al. Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass. Ann. Thorac. Surg. 60(3):1995;525-529.
2. Aldea G.S., Soltow L.O., Chandler W.L.et al. Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits. J. Thorac. Cardiovasc. Surg. 123(4):2002;742-755.
3. Spannagel M., Dietrich W., Beck A., Schramm W. High dose aprotinin reduces prothormbin and fibrinogen conversion in patients undergoing extracorporeal circulation for myocardial revascularization. Thromb. Haemost. 72:1994;159.
4. Chan C.W., Chan M.W., Liu M.et al. Kinetic analysis of a unique direct prothrombinase, fgl2, and identification of a serine residue critical for the prothrombinase activity. J. Immunol. 168(10):2002;5170-5177.
5. Levy J.H., Bailey J.M., Salmenpera M. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. Anesthesiology. 80(5):1994;1013-1018.
6. Carrel T., Bauer E., Laske A.et al. Low-dose aprotinin for reduction of blood loss after cardiopulmonary bypass. Lancet. 337(8742):1991;673.
7. Ovrum E., Brosstad F., Am Holen E.et al. Complete heparin-coated (CBAS) cardiopulmonary bypass and reduced systemic heparin dose; effects on coagulation and fibrinolysis. Eur. J. Cardiothorac. Surg. 10(6):1996;449-455.
8. Rapaport S.I., Rao L.V. The tissue factor pathway: how it has become a "prima ballerina" Thromb. Haemost. 74(1):1995;7-17.
9. Kojima T., Gando S., Kemmotsu O.et al. Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: role of tissue factor pathway inhibitor. J. Cardiothorac. Vasc. Anesth. 15(1):2001;60-64.
10. Wachtfogel Y.T., Hack C.E., Nuijens J.H.et al. Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation. Am. J. Physiol. 268(3 Pt 2):1995;H1352-H1357.
11. Ray M.J., Marsh N.A. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin. Thromb. Haemost. 78(3):1997;1021-1026.
12. Kazatchkine M.D., Fearon D.T., Silbert J.E., Austen K.F. Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. J. Exp. Med. 150(5):1979;1202-1215.
13. Wei M., Kuukasjarv P., Laurikka J.et al. Cardioprotective effect of pump prime aprotinin in coronary artery bypass grafting. Cardiovasc. Drugs Ther. 16:2002;37-42.
14. Olsson C., Siegbahn A., Halden E.et al. No benefit of reduced heparinization in thoracic aortic operation with heparin-coated bypass circuits. Ann. Thorac. Surg. 69(3):2000;743-749.
15. Parolari A., Alamanni F., Gherli T.et al. 'High dose' aprotinin and heparin-coated circuits: clinical efficacy and inflammatory response. Cardiovasc. Surg. 7(1):1999;117-127.
16. Mojcik C.F., Levy J.H. Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. Ann. Thorac. Surg. 71(2):2001;745-754.
17. Gu Y.J., Obster R., Haan J.et al. Biocompatibility of leukocyte removal filters during leukocyte filtration of cardiopulmonary bypass perfusate. Artif. Organs. 17(7):1993;660-665.
18. Jansen P.G., te Velthuis H., Huybregts R.A.et al. Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits. J. Thorac. Cardiovasc. Surg. 110(3):1995;829-834.
19. Butler J., Murithi E.W., Pathi V.L.et al. Duroflo II heparin bonding does not attenuate cytokine release or improve pulmonary function. Ann. Thorac. Surg. 74:2002;139-142.
20. Jansen P.G., Baufreton C., Le Besnerais P.et al. Heparin-coated circuits and aprotinin prime for coronary artery bypass grafting. Ann. Thorac. Surg. 61(5):1996;1363-1366.
21. Dhote-Burger P., Vuilleminot A., Lecompte T. Neutrophil degranulation related to the reperfusion of ischemic human heart during cardiopulmonary bypass. J. Cardiovasc. Pharmacol. 25(Suppl. 2):1995;S124-S129.
22. Englberger L., Kipfer B., Berdat P.A.et al. Aprotinin in coronary operation with cardiopulmonary bypass: does "low-dose" aprotinin inhibit the inflammatory response? Ann. Thorac. Surg. 73(6):2002;1897-1904.